Why the study?
There were no robust clinical markers for assessing prognosis in patients with heart failure with recovered left ventricular ejection fraction.
Does higher NT-proBNP level at the time of LVEF recovery predict LVEF relapse and a composite of HF hospitalization or all-cause death in patients with HF with recovered LVEF?
Population
3935 patients with HF with recovered LVEF and available NT-proBNP data
Comparison
7 different NT-proBNP groups at the time of LVEF recovery
Design
Retrospective cohort study
Key result
Near-normal NT-proBNP levels (125-299 pg/mL) at LVEF recovery were associated with a 46% higher risk of LVEF relapse and an 82% higher risk of HF hospitalization or death compared to normal levels.
Authors
Loading...
May support closer surveillance after LVEF recovery; leaves open whether NT-proBNP-guided therapy improves outcomes.
Cohort (n=3,935)
Does higher NT-proBNP level at the time of LVEF recovery predict LVEF relapse and a composite of HF hospitalization or all-cause death in patients with HF with recovered LVEF?
Effect estimate: 46% higher risk (LVEF relapse) and 82% higher risk (composite)
NT-proBNP measured at the time of LVEF recovery is an independent, dose-dependent predictor of LVEF relapse and adverse clinical outcomes in patients with HF with recovered LVEF.
Kodur et al. (2025) conducted a cohort in Heart failure with recovered left ventricular ejection fraction (LVEF) (n=3,935). NT-proBNP levels vs. Normal NT-proBNP levels (<125 pg/mL) was evaluated on LVEF relapse (decrease in LVEF by ≥10% to <50%) and a composite of HF hospitalization or all-cause death (46% higher risk (LVEF relapse) and 82% higher risk (composite)). Near-normal NT-proBNP levels (125-299 pg/mL) at LVEF recovery were associated with a 46% higher risk of LVEF relapse and an 82% higher risk of HF hospitalization or death compared to normal levels.